top of page
Mitral Valve Repair By Anterior Leaflet Augmentation
Transcatheter Solution designated to Functional Mitral Regurgitation
About LeaFix
LeaFix Medical Ltd. is an innovative structural heart medical device company developing the LeaFix Mitral System. The system introduces a minimally invasive transcatheter Mitral Valve Repair designed specifically for the treatment of Functional Mitral Regurgitation (FMR). By delivering a transcatheter implant that directly augments the anterior mitral leaflet, the system effectively restores leaflet coaptation while preserving the heart’s natural anatomical structure.
The Market
Trans-catheter mitral valve repair was valued at $1.6 billion in 2023 and is expected to reach $2.45 billion by 2030 exhibiting a CAGR of 6.1%.
bottom of page